|drug368||Azithromycin 500 milligram (mg) oral Tablet Wiki||1.00|
|D014777||Virus Diseases NIH||0.11|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This is a Phase 3 randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pacritinib in hospitalized patients with severe COVID-19 with or without cancer.
Description: The proportion is calculated as the number of patients who progress divided by the total number of patients in the ITT population.Measure: Proportion of patients who progress to IMV and/or ECMO or death during the 28 days following randomization Time: 28 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports